---
title: "Immune-evading universal donor iPSC-derived NK cells: Frontiers in Immunology original research"
id: "frontiers-in-immunology-13-immune-evading-universal-donor-ipsc-derived-natural-killer-cells-enable-off-the"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-immune-evading-universal-donor-ipsc-derived-natural-killer-cells-enable-off-the"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1938206"
published_at: "2026-10-29T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Immune-evading universal donor iPSC-derived NK cells: Frontiers in Immunology original research
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-immune-evading-universal-donor-ipsc-derived-natural-killer-cells-enable-off-the
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1938206)
- **Published At:** 2026-10-29T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The provided JINA extract identifies an ORIGINAL RESEARCH article in Frontiers in Immunology with the title referencing **immune-evading**, **universal donor**, **iPSC-derived natural killer cells** and off-the-shelf cancer immunotherapy. - The JINA content supplied contains site navigation, journal sections, and repeated header material but does not include the article abstract, methods, results, or conclusions. - The source did not report trial design, dosing, in vitro or in vivo data, sample sizes, or endpoints in the extracted content. Those core methodological details are absent from the provided text. - Article context: the journal’s topical sections include NK and Innate Lymphoid Cell Biology and Cancer Immunity and Immunotherapy, suggesting likely subject-area placement but not specific study scope. - What is missing and needs retrieval: author list, affiliations, publication date, stated aims, experimental design, primary and secondary endpoints, statistical analyses, safety and efficacy findings, and declared limitations. - Practical next steps for clinicians and researchers: obtain the full article text or abstract from the journal site; verify experimental systems (cell lines, animal models, clinical cohorts), gene edits or immune-evasion strategies used, and any translational or regulatory commentary supplied by the authors. - Unanswered clinical questions that cannot be resolved from the extract: whether the cells demonstrated cytotoxicity in relevant tumor models, whether immune-evading modifications impacted host rejection, manufacturing scalability, and any reported adverse events or off-target effects. - The extract supports only metadata-level reporting; no clinical or experimental claims can be made beyond the article title and placement in Frontiers in Immunology.
## Clinical Analysis & Structured Key Points
Frontiers | Immune-evading universal donor iPSC-derived natural killer cells enable off-the-shelf cancer immunotherapy ORIGINAL RESEARCH article Front. Immunol. , 29 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1938206 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Advancing the Clinical Application of Natural Killer Cell Therapies 30k views 10 articles Editor & Reviewers Edited by X C Xiaofang Che Reviewed by M T Marina Tarunina T W Tongjie Wang T S Tomomi Sanomachi Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Figure 4 View in article Figure 5 View in article Figure 6 View in article ORIGINAL RESEARCH article Front. Immunol. , 29 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1938206 Immune-evading universal donor iPSC-derived natural killer cells enable off-the-shelf cancer immunotherapy M I Masayuki Ito 1 * H T Hirofumi Tsuzuki 1 M A Michael A. Secinaro 1 S K Shannon Kreuser 1 K O Kaori Oda 1 B K Borith Kheng 1 L G Louie Galitan 1 J A Julie A. Vergara 1 I T Ippei Takeuchi 2 S L Sarah L. Ameny 1 M G Mary G. Prieve 1 M T Mark T. Orr 1 +4 more T Y Taku Yoshida 1 1. Research, Universal Cells, Inc., Seattle, WA, United States 2. Research, Astellas Institute for Regenerative Medicine, Westborough, MA, United States Article metrics View details Abstract Background: Natural killer (NK) cells are a promising modality for cancer immunotherapy due to their intrinsic ability to eliminate malignant cells and their safety profile, while their clinical application remains limited by donor variability, immune rejection, and challenges in large-scale manufacturing. Methods: We developed a multi–gene-edited universal donor induced pluripotent stem cell (iPSC)-derived NK cell (UDC-NK) platform. First, the engineered iPSC line was generated by disrupting B2M and RFXANK to eliminate HLA class I and II molecules and by introducing a single-chain HLA-E for immune evasion. In addition, a safety switch system was incorporated to ensure controllability. We also developed a novel feeder-free, scalable manufacturing process for cryopreserved UDC-NK cells for off-the-shelf cellular therapy. Results: We succeeded in generating large numbers of UDC-NK cells with an activated phenotype. UDC-NK cells exhibited robust cytotoxicity and cytokine production against CD20 + lymphoma cell lines in vitro , which were further enhanced in the presence of Rituximab. UDC-NK cells effectively demonstrated immune evasion from allogeneic T cell– and NK cell–mediated responses. In addition, UDC-NK cells could be selectively eliminated via a herpes simplex virus thymidine kinase–based safety switch upon ganciclovir treatment in vitro . In disseminated B-cell lymphoma models, combination treatment with UDC-NK cells and Rituximab resulted in near-complete tumor growth inhibition and significantly prolonged survival. Conclusions: These findings establish UDC-NK cells as a scalable off-the-shelf cell therapy platform with enhanced anti-tumor efficacy and built-in safety control, supporting their potential clinical application in combination with antibody-based cancer therapies. 1 Introduction Cancer immunotherapy has rapidly advanced in recent years and is now widely recognized as a major pillar of cancer treatment alongside surgery, chemotherapy, targeted therapy, and radiotherapy. The development of immune checkpoint inhibitors and adoptive cell therapies has significantly improved outcomes for patients with several malignancies ( 1 – 3 ). Immune cell-based cancer therapies have also shown remarkable clinical success in hematological cancers. Autologous chimeric antigen receptor (CAR) T-cell therapies targeting CD19 and BCMA have produced durable responses in patients with relapsed or refractory B-cell and plasma cell malignancies and have transformed the treatment landscape for diseases such as acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma ( 2 ). These successes have established adoptive cell therapy as a powerful modality for cancer treatment and have stimulated intense interest in the development of next-generation cellular immunotherapies. Despite these advances, the broader clinical application of autologous CAR-T cell therapies remains limited by several practical and biological challenges ( 1 , 3 , 4 ). Manufacturing of autologous products requires individualized production from each patient, involving complex and labor-intensive processes that contribute to high treatment costs. In addition, the manufacturing timeline for autologous therapies typically requires several weeks, which can delay treatment for patients with rapidly progressing diseases. Product variability resulting from differences in patient-derived starting material can also affect therapeutic consistency and efficacy. Furthermore, autologous T-cell therapies are associated with potentially severe toxicities, including cytokine release syndrome and neurotoxicity. These limitations have stimulated growing interest in alternative immune cell platforms that enable scalable, standardized, and readily available cellular therapies ( 3 ). Natural killer (NK) cells are innate immune lymphocytes that play a critical role in the immune surveillance against infected or transformed cells. Unlike T cells, NK cells do not require antigen-specific priming and can recognize malignant cells through a balance of activating and inhibitory receptor signals ( 5 , 6 ). This mechanism enables NK cells to detect stressed or transformed cells that have downregulated major histocompatibility complex (MHC) molecules, a phenomenon commonly referred to as “missing-self” recognition ( 7 ). Upon activation, NK cells exert potent cytotoxic effects through multiple mechanisms, including the release of perforin and granzymes, as well as death receptor–mediated pathways such as Fas ligand and TRAIL. In addition to direct tumor cell killing, NK cells produce cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), which can enhance antitumor immunity and promote interactions with other immune cell populations ( 8 ). NK cells can also eliminate antibody-coated tumor cells through antibody-dependent cellular cytotoxicity (ADCC) mediated by Fc receptors, allowing them to cooperate with therapeutic monoclonal antibodies ( 9 , 10 ). These diverse mechanisms make NK cells an attractive cellular platform for cancer immunotherapy. However, current NK cell–based therapies face several limitations that hinder their widespread clinical implementation. Primary NK cells derived from peripheral blood or cord blood often exhibit donor-to-donor variability and limited expansion potential, complicating large-scale manufacturing. In addition, NK cells typically show limited persistence after infusion, which may restrict long-term therapeutic efficacy. NK cells are also sensitive to cryopreservation, which can impair their biological activity and antitumor efficacy post-thaw. Consequently, generating consistent, scalable, cryopreserved NK cell products suitable for clinical use remains a major challenge for the field ( 11 – 13 ). Induced pluripotent stem cells (iPSCs) offer a promising strategy to address many of these limitations. iPSCs possess the capacity for unlimited self-renewal and can differentiate into a wide range of cell types, including NK cells ( 14 , 15 ). Importantly, iPSC-based platforms enable the generation of large numbers of standardized cellular products derived from a well-characterized master cell bank, thereby facilitating scalable manufacturing of off-the-shelf cell therapies ( 15 ). In addition, iPSCs provide an ideal platform for extensive genetic engineering at the pluripotent stage, allowing the introduction of multiple genetic modifications designed to enhance the efficacy, persistence, and safety of derived immune cells. These advantages make iPSC-derived immune cells an attractive approach for developing next-generation cellular immunotherapies ( 16 – 18 ). More recently, universal donor iPSC (UDC-iPSC) technologies using adeno-associated virus (AAV)–mediated gene editing have been developed to overcome immune rejection following allogeneic cell transplantation. By disrupting the B2M and RFXANK genes, which are required for surface expression of HLA class I and class II molecules, respectively, and introducing a single-chain HLA-E construct, UDCs and their differentiated derivatives can evade recognition by host T cells while avoiding NK cell–mediated rejection ( 19 – 21 ). These strategies have the potential to generate broadly compatible allogeneic cellular therapeutics that can be administered across multiple patients without HLA matching. Consequently, UDC technologies represent a promising approach for enabling universal, off-the-shelf cell therapy platforms. Recent advances in iPSC-derived NK cell technologies have further accelerated the development of next-generation, off-the-shelf cellular immunotherapies ( 16 – 18 ). Several groups have demonstrated the feasibility of generating large numbers of functional NK cells from iPSCs under clinically scalable manufacturing conditions, leading to the emergence of multiple clinical-stage iPSC-NK cell products ( 15 , 17 , 22 , 23 ). In parallel, extensive genetic engineering strategies have been implemented to enhance the therapeutic performance of iPSC-derived NK cells. These approaches include the introduction of high-affinity and non-cleavable CD16 variants to improve antibody-dependent cellular cytotoxicity (ADCC) ( 17 , 21 ), expression of cytokine support systems such as membrane-bound IL-15 to enhance persistence and functionality ( 17 , 22 , 23 ), incorporation of chimeric antigen receptors (CARs) to increase tumor specificity ( 16 , 17 ), and genetic modifications designed to improve resistance to the immunosuppressive tumor microenvironment ( 22 , 23 ). More recently, immune-evasive engineering strategies, including modulation of HLA molecules and expression of inhibitory ligands, have been developed to reduce host immune rejection and prolong persistence following allogeneic administration ( 19 , 23 – 25 ). Collectively, these advances have established genetically engineered iPSC-derived NK cells as a highly promising platform for the development of universal, off-the-shelf cancer immunotherapies capable of combining enhanced persistence, immune evasion, and potent antitumor activity. In this study, we developed universal donor iPSC (UDC-iPSC)-derived NK cells (UDC-NK) designed to enhance immune evasion, safety, and antitumor efficacy. The engineered UDC clone incorporates multiple genetic modifications, including disruption of B2M and RFXANK to eliminate HLA class I and class II expression, expression of a single-chain HLA-E construct to prevent NK cell–mediated rejection, introduction of a high-affinity FCGR3A (F158V) variant to enhance ADCC ( 21 ), and integration of a herpes simplex virus thymidine kinase (HSV-TK) suicide gene as an inducible safety switch ( 26 – 28 ). We also established a feeder-free and scalable manufacturing process capable of generating large numbers of functional NK cells. Using this platform, we efficiently generated NK cells from UDCs and comprehensively characterized their phenotype and function in vitro and in vivo . We evaluated surface marker expressions, cytotoxic effector functions including natural cytotoxicity and ADCC, cytokine production, and the immune-evasive properties of the engineered NK cells in the context of allogeneic immune recognition. In addition, we validated the functionality of the integrated HSV-TK suicide gene as an inducible safety switch in vitro . Finally, the antitumor activity of UDC-NK cells was assessed in vitro and validated in vivo using xenograft tumor models to determine their therapeutic potential. Collectively, this study establishes a genetically engineered iPSC-derived NK cell platform that may enable the development of broadly compatible, off-the-shelf NK cell therapies for cancer. 2 Materials and methods 2.1 Cells and cell culture The human WT iPSC line NIH3 c.C4 was established by single-cell cloning in-house from a clinical-grade iPSC bank (Lonza, Basel, Switzerland) and used for gene editing. All parental and gene-edited iPSC lines were maintained on Vitronectin XF™ (Stemcell Technologies, Vancouver, BC, Canada)–coated culture vessels in mTeSR1 or TeSR-E8 medium (Stemcell Technologies) in a 37 °C, 5% CO 2 , and 5% O 2 incubator. Chronic myelogenous leukemia cell line K562, CD20 + non-Hodgkin lymphoma (NHL) cell lines Raji, Ramos, Daudi, Mino, SU-DHL-4, SU-DHL-5, SU-DHL-6, P3HR-1 cells were obtained from American Type Culture Collection (Manassas, VA, USA). Granta-519 NHL cell line was purchased from Creative Bioarray (Shirley, NY, USA). K562 cells engineered to express HiBiT protein were purchased from Promega (Madison, WI, USA). All cells were cultured in RPMI 1640 media supplemented with 2 mM GlutaMAX™ (Thermo Fisher Scientific, Waltham, MA, USA) and with 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific). For ADCC assays, NucLight™ Red-expressing Ramos cells were established by transducing cells with the IncuCyte ® NucLight™ Red Lentivirus Reagent (Sartorius, Ann Arbor, MI, USA), followed by puromycin selection. For in vivo studies, Raji-Luc and Daudi-Luc cells were established by infection with IVISbrite™ Red F-luc-Puromycin Lentiviral Particles (Revvity, Waltham, MA, USA) to introduce a Red-Shifted luciferase and a GFP reporter gene, followed by single-cell cloning. 2.2 Gene editing to establish universal donor iPSC (UDC-iPSC) Establishing universal donor iPSC (UDC-iPSC) engineered to express high affinity CD16A F158V variant for the manufacturing UDC-NK cells for clinical applications, has been described previously ( 29 ). Briefly, the NIH3 c.7C2 iPSC line, which was used for UDC-NK manufacturing, was generated from NIH3 c.C4 WT iPSC clone through the multiple rounds of gene-editing, which includes (1) knocking out the B2M and RFXANK genes to eliminate surface expression of HLA Class I and Class II molecules to escape allogeneic rejection mediated by T cells, (2) introduction of a single-chain HLA-E chimeric receptor to protect differentiated cells from allogeneic rejection mediated by CD94/NKG2A-expressing allogeneic NK cells ( 19 ), (3) ganciclovir-inducible thymidine kinase gene cassettes as a safety switch to reduce the risk of severe, unwanted adverse events following administration of NK cell product to cancer patients ( 26 , 28 ), and (4) FCGR3A F158V gene coding naturally occurred high-affinity CD16A variant to improve ADCC in combination with therapeutic antibodies. iPSC line NIH2 c.2B9 was established by disrupting B2M genes. All gene-editing was performed using recombinant adeno-associated viruses. 2.3 Cell differentiation NK cell differentiation from iPSCs was performed using a modified protocol described previously ( 15 ). Briefly, 1,000–2,000 Trypsin-adapted single iPSCs were seeded into each well of a 24-well AggreWell™ 800 plate (Stemcell Technologies) in APEL2 medium (Stemcell Technologies) supplemented with 40 ng/mL human stem cell factor (SCF; PeproTech, Rocky Hill, NJ, USA), 20 ng/mL human vascular endothelial growth factor (VEGF; R&D Systems, Minneapolis, MN, USA), and 20 ng/mL human bone morphogenetic protein 4 (BMP-4; R&D Systems) to promote embryoid body (EB) formation. Cells were cultured at 37 °C under 5% CO 2 and 5% O 2 . Half-medium changes were performed every other day. EBs were maintained under these conditions for 14 days to promote the generation of CD34 + hematopoietic progenitor cells (HPCs). On day 14, HPCs were harvested in DMEM/F-12 medium (Thermo Fisher Scientific) supplemented with 15% heat-inactivated human AB serum (BioIVT, Westbury, NY, USA), 5 ng/mL IL-3 (first week only), 10 ng/mL IL-15, 20 ng/mL IL-7, 20 ng/mL SCF, and 10 ng/mL Flt3 ligand (PeproTech). In addition, 35 nM UM171 (Xcess Biosciences, San Diego, CA, USA), a pyrimidoindole-derived small molecule previously reported to promote the self-renewal and expansion of hematopoietic stem cells and progenitor cells, was added to stabilize HPCs and enhance NK cell differentiation efficiency ( 30 – 32 ). The HPCs were subsequently replated onto culture vessels coated with RetroNectin™ (Takara Bio, Shiga, Japan) and human Delta-like ligand 4–Fc protein (DLL4; ACRO Biosystems, Beijing, China) to facilitate Notch signaling–mediated NK lineage commitment. Cells were further cultured for 3 weeks to promote differentiation into immature CD56 + UDC-NK cells. Culture medium was refreshed every 3–4 days throughout the differentiation period. Cells were maintained at 37 °C under 5% CO 2 in air during this stage. For the assessment of immune evasion in UDC-NK cells, the B2M KO iPSC clone NIH2 c.2B9 was differentiated into CD14 + myeloid cells using the STEMdiff™ Hematopoietic Kit (STEMCELL Technologies) following previously published protocols ( 33 ). 2.4 Activation and expansion of UDC-NK cells CD56 + immature UDC-NK cells were harvested and resuspended at a density of 2x10 5 cells/mL in CTS™ NK-Xpander™ Medium (Thermo Fisher Scientific) supplemented with 7.5% heat-inactivated human AB serum, 10 ng/mL IL-15, 10 ng/mL IL-18 (R&D Systems), and 10 ng/mL IL-21 (Peprotech). NK cells were seeded into culture vessels pre-coated with 0.89 μg/mL anti-human NKp30 antibody (BioLegend, San Diego, CA, USA), 0.89 μg/mL anti-DNAM-1 antibody (Bio-Rad Laboratories, Hercules, CA, USA), and 0.89 μg/mL RetroNectin™. Cells were cultured for 3 days at 37 °C under 5% CO 2 in air to stimulate the maturation and proliferation of immature NK cells. After 3 days of activation with anti-NKp30 and anti-DNAM-1 antibodies, NK cells were harvested and resuspended in CTS™ NK-Xpander™ Medium containing 7.5% heat-inactivated human AB serum, 10 ng/mL IL-15, and 10 ng/mL IL-18. The cells were then transferred at a density of 4x10 5 cells/mL to disposable spinner flasks (Corning, Corning, NY, USA) placed on a magnetic stirrer (Chemglass Life Science, Vineland, NJ, USA) for further expansion at 45–55 rpm in a 37 °C incubator with 5% CO 2 . Following initiation of spinner flask culture, an equal volume of fresh medium containing the same supplements was added to the culture. NK cells were expanded in spinner flasks for 4 days. 3-day NK Activation and 4-day NK Expansion cycle was repeated three times. After three cycles of activation and expansion, NK cells were harvested and cryopreserved in CryoStor ® CS-10 (Stemcell Technologies) for further characterization. At harvest, NK cell purity was typically >99% among CD45 + CD56 + cells. In selected experiments, the cycle was repeated up to seven times to evaluate the robustness and scalability of the manufacturing process. 2.5 Flow cytometry Flow cytometry was performed using an Attune NxT flow cytometer (Thermo Fisher Scientific), and the data were analyzed using FlowJo™ software (FlowJo, Ashland, OR, USA). Details of antibodies used in this study are provided in Supplementary Table 1 . 2.6 Ganciclovir sensitivity of UDC-NK cells To assess the function of the HSV-TK-based safety switch in vitro , NK cells were seeded into a 96-well flat-bottom plate in the presence of 10 ng/mL IL-15 and a titrated concentration of ganciclovir (MilliporeSigma, Burlington, MA, USA) and cultured at 37 °C in a humidified incubator with 5% CO 2 . Four days after the initiation of ganciclovir treatment, NK cell viability was measured using CellTiter ® -Glo 2.0 Cell Viability Assay (Promega). 2.7 Immune evasion of UDC-NK cells from allogeneic PBMC T cells and NK cells To assess the activation of allogeneic T cells after co-culture with UDC-NK cells, CD4 + an
## Related Clinical Research

- [Incidence and Impact of ALC-only Progression in Chronic Lymphocytic Leukemia](https://medichelpline.com/clinical-feed/pubmed-42466974.md) (DOI: 10.1182/bloodadvances.2026020680)
- [Low-dose vemurafenib plus rituximab (Scripps regimen) for frontline and relapsed hairy cell leukem](https://medichelpline.com/clinical-feed/pubmed-42308249.md) (DOI: 10.1182/bloodadvances.2025019243)
- [Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL](https://medichelpline.com/clinical-feed/clinicaltrials-nct05947851.md) (DOI: NCT05947851)
- [Neoehrlichia mikurensis Infection Causing Recurrent Fever in an Immunocompromised Patient, Netherl](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-neoehrlichia-mikurensis-infection-in-immunocompromised-patient-the-netherlands.md)
- [Vedolizumab for Immunodeficiency-Associated Enteropathy: Full Article Not Included in Source](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-vedolizumab-treatment-in-adults-with-immunodeficiency-associated-enteropathy-a.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.